| May 9, 2019
|
| May 15, 2019
|
| February 11, 2021
|
| April 1, 2020
|
| July 1, 2020 (Final data collection date for primary outcome measure)
|
| Beck II Self-Applied Depression Inventory (BDI-II) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ] The primary outcome will be measured using the BDI-II (Beck et al., 1996). This is a self-report inventory for measuring the severity of depression, consisting of 21 multiple-choice questions with each answer being scored on a scale ranged from 0 to 3. It was translated and validated into Spanish with a reliability of .89 (Sanz et al., 2005). The standardized cutoffs are: 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression; 29-63: severe depression.
|
| Beck II Self-Applied Depression Inventory (BDI-II) [ Time Frame: Change from Baseline severity of depression at 1 week after intervention, after 6 months and after 12 months. ] It is self-report inventory for measuring the severity of depression, with 21-question multiple-choice, each answer being scored on a scale value of 0 to 3. The standardized cutoffs are: 0-13: minimal depression. 14-19: mild depression. 20-28: moderate depression. 29-63: severe depression (Beck et al., 1996).
|
|
|
- International Neuropsychiatric Interview (MINI) [ Time Frame: Baseline ]
It is a short-term structured diagnostic interview that explores the main psychiatric disorders of Axis I of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and International Classification of Diseases (ICD-10) (Ferrando et al., 2000).
- Comorbidity with chronic diseases [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Comorbidity with chronic diseases will be determined according to the International Classification of Diseases (ICD-10) (WHO, 2010): diabetes (glucose concentration (mg/dl), glycated hemoglobin (%), creatinine), arterial hypertension and diseases of lipid metabolism. In patients with chronic heart disease, coagulation variables will be added. They will be collected from the last blood test or control measurements of the clinical history, taken by their general practitioner (GP) or nurse (assuming they were taken over the past 3 months). Otherwise, their GP will be asked for a blood control test. It is estimated that approximately 50% of these patients will present some comorbidity (Katon, 2003). Anthropometric measures will also be collected (weight, size and perimeter of the waist).
- European Quality of Life-5 Dimensions questionnaire (EQ-5D) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Health-related quality of life will be measured using the European Quality of Life-5 Dimensions questionnaire (EQ-5D) (Brooks & De Charro, 1996; The EuroQol Group, 1990). EQ-5D scores will be used to calculate the quality-adjusted life year (QALY) during the monitoring period by adjusting the length of time affected by the health result by the utility value. It contains five health dimensions (mobility, selfcare, usual activities, pain/discomfort and anxiety/depression) and each of these has three levels (no problems, slight problems or moderate and severe problems). The EQ records the patient's self-rated health on a vertical visual analogue scale of 20 centimeters (VAS). The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgment. Patients mark the point on the vertical line that best reflects their assessment of their current global health status (Badia, Roset, Montserrat, Herdman, & Segura, 1999).
- Physical activity questionnaire (IPAQ-SF) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Physical activity will be measured using the International Physical Activity Questionnaire-Short Form (IPAQ-SF) (Kim, Park, & Kang, 2013). It assesses the levels of habitual physical activity over the last 7 days. It has 7 items and records the activity of four intensity levels: vigorous-intensity activity, moderate-intensity activity (walking and sitting). We will use the validated Spanish version (Roman-Viñas et al., 2010). IPAQ-SF has acceptable validity for the measurement of total and vigorous physical activity and poor validity for moderate activity and good reliability (Kurtze, Rangul, & Hustvedt, 2008).
- Mediterranean Diet Adherence Screener (MEDAS) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the 14-item Mediterranean Diet Adherence Screener (MEDAS), developed within the PREDIMED study group (Martínez-González et al., 2010). It includes items on food consumption and intake habits: the use of olive oil as the main source of cooking fat, preference for white meat over red meat, servings of vegetables, portions of fruit, red meat or sausages, servings of animal fat, sugar-sweetened beverages, red wine, legumes, fish, commercial pastries and dressing food with a traditional sauce made of tomatoes, garlic, onion, or leeks sautéed in olive oil. The total score ranges from 0 to 14, with a higher score indicating a better accordance with the Mediterranean diet (Schröder et al., 2011).
- Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). To measure sleep quality and patterns in adults. It differentiates between "poor" and "good" sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the past month. It consists of 19 self-applied questions and 5 questions that request the evaluation of the patient's bedmate or roommate (these are not scored). Answers range from 0 (no difficulty) to 3 (severe difficulty). The overall score ranges from 0 to 21 points. In its Spanish version, the Cronbach's alpha coefficient is .81, sensitivity of 88.63% and specificity of 74.99%. We will use the validated Spanish version (Royuela Rico & Macías Fernández, 1997).
- Patient Activation Questionnaire (PAM) in relation to the management of their health [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the Patient Activation Questionnaire (PAM) with regard to the management of their health. It evaluates the patient's perceived knowledge, skills, and confidence to engage in self-management activities. It has 13 items, a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The resulting score (between 0 and 100) places the individual at one of four levels of activation, each of which reveals insight into a range of health-related characteristics, including behaviors and outcomes. Higher scores indicate higher levels of activation (Hibbard et al., 2004). This scale is only validated in Spanish for chronic patients. It had an item separation index for the parameters of 6.64 and a reliability of .98 (Moreno Chico, González de Paz, Monforte Royo, Navarro Rubio, & Gallart Fernández Puebla, 2018).
- Social support questionnaire (MOS) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
It will be measured by the Medical Outcomes Study Social Support Survey (MOS-SS) (Sherbourne & Stewart, 1991). It is a self-report instrument consisting of four subscales (emotional/informational, tangible, affectionate, and positive social interaction) and an overall functional social support index. It has a good reliability (Cronbach's alpha ≥ .91) and is quite stable over time. It has 19 items, a five-point Likert scale. Higher scores indicate more support. We will use the Spanish validated version (de la Revilla-Ahumada L, Luna del Castillo J, & Bailón Muñoz E, 2005).
- The Self-Efficacy Scale [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using by the Self-Efficacy Scale (Sherer et al., 1982). To measure General Self-Efficacy subscale (17 items including individuals' beliefs in their ability to perform well in a variety of situations) and Social Self-Efficacy subscale (6 items). It contains 23 items that are rated on a 14-point scale (ranging from strongly agree to strongly disagree). Higher scores indicate higher levels of self-efficacy. It has a Cronbach coefficient alpha of .86 for General Self-efficacy subscale and .71 for the Social Self-efficacy subscale. The unpublished Spanish version was translated by Godoy in 1990 (Lopez-Torrecillas, García, Cañadas, Ramirez Ucles, & de la Fuente, 2006).
- Sense of coherence questionnaire of Antonovsky [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the Sense of Coherence (SOC) questionnaire by Antonovsky (Antonovsky, 1993). It values the personal disposition towards the assessment of vital experiences. It measures the sense of coherence, comprehensibility, manageability and meaningfulness. It has 13 items scoring between 13 and 91 points. It has consistency rates of between .84 and .93. Higher scores (after reversal of the inverted items) indicate a higher sense of coherence. We will use the validated Spanish version (Moreno, B., Alonso, M., & Álvaréz, 1997).
- Health Literacy Europe questionnaire (HLS-EUQ16) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the Health Literacy Europe Questionnaire (HLS-EUQ16) (Sørensen et al., 2015). It can indicate that the probability of functional literacy in limited health is high, a possibility of functional literacy in limited health, and a functional health literacy in adequate health. It contains 16 items. Higher scores indicate better health literacy. It presents a high consistency (Cronbach's alpha of .982) in the Spanish validation (Nolasco et al., 2018).
- Irrational Procrastination Scale (IPS) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
Measured using the Irrational Procrastination Scale (IPS) (Steel, 2010). To measure general procrastination (dysfunctional delay). It has 9 items, rated on a 5-point Likert scale, with higher scores (after reversal of the three procrastination-inconsistent items) indicating a higher level of procrastination. Its Cronbach's alpha value is 0.90. We will use the validated Spanish version (Guilera et al., 2018).
- Client Service Receipt Inventory (CSRI) [ Time Frame: Change from baseline, immediately after the intervention and at six and 12-month follow-up. ]
It will be measured using the Client Service Receipt Inventory (CSRI) (Knapp, 2001). This data may be used for a wide range of applications, including estimates of the costs of service receipt. To collect information on the entire range of services and supports used by study participants. It retrospectively collects data on the use of services over the past 6 months (e.g., rates of use of individual services, mean intensity of service use, rates of accommodation use over time). We will use the validated Spanish version (Vazquez-Barquero, Gaite, Cuesta, Garcia, & Knapp, 1997).
|
- International Neuropsychiatric Interview (MINI) [ Time Frame: Baseline ]
It is a short-term structured diagnostic interview that explores the main psychiatric disorders of Axis I of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and International Classification of Diseases (ICD-10) (Ferrando et al., 2000).
- Comorbidity with chronic diseases [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
Comorbidity with chronic diseases will be collected according to International Classification of Diseases (ICD-10): diabetes (glucose concentration (mg / dl), glycated hemoglobin (%), creatinine), arterial hypertension, diseases of lipid metabolism. In patients with chronic heart disease, coagulation variables will be added. Anthropometric measures will also be collected (Weight: A precision scale will be used, easy to calibrate and this will be done every day, after each measurement the return to zero level will be checked. Size: It will be measured in vertical position. Perimeter of the waist: The midpoint between the last rib and the iliac crest will be located). They will be collected by clinical history in the last blood test or control measurement made by your family doctor or nurse (as long as it was taken in less than 3 months). Otherwise, their family doctor will be asked for a control analysis.
- European Quality of Life-5 Dimensions questionnaire (EQ-5D) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
Generic instrument of quality of life related to health. The EQ-5D scores will be used to calculate the quality adjusted for years of life (QALY) during the monitoring period by adjusting the length of time affected by the health result by the value of the utility.
It contains five dimensions of health (mobility, personal care, daily activities, pain / discomfort and anxiety / depression) and each of them has three levels of seriousness (without problems, some problems or moderate problems and serious problems).
The second part of the EQ-5D is a Visual Analogue Scale (VAS) of 20 centimeters, millimeter, ranging from 0 (worse health status imaginable) to 100 (best imaginable health status). In it, the individual must mark the point in the vertical line that best reflects the assessment of their global health status today (Badia et al., 1999).
- Physical activity questionnaire (IPAQ-SF) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To assess the levels of habitual physical activity in the period of the last 7 days. It has 9 items and records the activity of four intensity levels: vigorous-intensity activity such, moderate-intensity activity such, walking and sitting (Kim, Park & Kang, 2012).
- Adhesion to the Mediterranean Diet questionnaire (PREDIMED) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
A 14-item tool of adherence to the Mediterranean diet. Less than 9 points, means low adhesion, greater than 9 points, it means good adherence (Martínez-González et al., 2012).
- Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To measure the quality and patterns of sleep in the older adult. It differentiates "poor" from "good" sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. There are several questions that request the evaluation of the client's bedmate or roommate, these are not scored, nor reflected in the attached instrument (Buysse, 1989).
- Patient Activation Questionnaire (PAM) in relation to the management of their health [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
It evaluates the patient's perceived knowledge, skills, and confidence to engage in self-management activities. It has 13 items, a Likert scale from 1 (strongly disagree) to 4 (strongly agree). They score between 0 and 100 and it places the individual at one of four levels of activation (Hibbard et al., 2004).
- Social support questionnaire (MOS) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
It is a self-report instrument consisting of four separate social support subscales (emotional/informational, tangible, affectionate, and positive social interaction) and an overall functional social support index. It has 19 items, a five-point Likert scale. A higher score for an indicates more support (de la Revilla Ahumada, 1991).
- The Self-Efficacy Scale [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To measure general self-efficacy (individuals' belief in their ability to perform well in a variety of situations) and social self-efficacy. It contains 23 items that are rated on a 14-point scale with the anchors agree strongly and disagree strongly. Higher scores indicate higher levels of self-efficacy (Sherer et al.,1982).
- Sense of coherence questionnaire of Antonovsky [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
It values the personal disposition towards the valuation of the vital experiences. It measures the sense of coherence, comprehensibility, manageability, meaningfulness. It has 13 items that score ranges between 13 and 91 points (Antonovsky, 1993).
- Health Literacy Europe questionnaire (HLS-EUQ16) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To measure the level of health literacy. It can indicate that the probability of functional literacy in limited health is high, a possibility of functional literacy in limited health, and a functional health literacy in adequate health (Sørensen et al., 2015).
- Irrational Procrastination Scale (IPS) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To measure general procrastination (dysfunctional delay). It has nine items, rated on a 5-point Likert scale, with higher scores (after reversal of the three procrastination-inconsistent items) indicating higher degree of procrastination (Guilera, 2018).
- Client Service Receipt Inventory (CSRI) [ Time Frame: Baseline, 1 week after intervention, after 6 months, after 12 months. ]
To collect information on the whole range of services and supports study participants may use. It collects retrospectively the data on the use of services during the previous 6 months (e.g., rates of service use of individual services, mean intensity of service use, rates of use of accommodation over time) (Knapp, 1995).
|
| Not Provided
|
| Not Provided
|
| |
| Lifestyle Modification Program in the Prevention and Treatment of Depression
|
| Effectiveness and Cost-effectiveness of a Lifestyle Modification Program in the Prevention and Treatment of Subclinical, Mild and Moderate Depression in Primary Care: A Randomized Clinical Trial Protocol
|
|
Introduction:
Major depression is a highly prevalent pathology that is currently the second most common cause of disease-induced disability in our society. The onset and continuation of depression may be related to a wide variety of biological and psychosocial factors, many of which are linked to different lifestyle aspects. Therefore, health systems must design and implement health promotion and lifestyle modification programs, taking into account personal factors and facilitators. The main objective of this work is to analyze the utility and cost-effectiveness of an adjunctive treatment program for subclinical, mild or moderate depression in Primary Care patients, based on healthier lifestyle recommendations. Secondary objectives include the analysis of the effectiveness of the intervention in comorbid chronic pathology and the measurement of the influence of personal factors on lifestyle modification.
Methods and analysis:
A randomized, multicenter pragmatic clinical trial with 3 parallel groups consisting of primary healthcare patients suffering from subclinical, mild or moderate depression. The following interventions will be used: 1. Usual antidepressant treatment with psychological advice and/or psychotropic drugs prescribed by the General Practitioner (treatment-as-usual, TAU). 2. TAU + Lifestyle Modification Program (LMP). A program to be imparted in 6 weekly 90-minute group sessions, intended to improve the following aspects: behavioral activation + daily physical activity + adherence to the Mediterranean diet pattern + sleep hygiene + careful exposure to sunlight. 3. TAU + LMP + ICTs: healthy lifestyle recommendations (TAU+LMP intervention) + monitoring using ICTs (a wearable smartwatch). The primary outcome will be the depressive symptomatology and the secondary outcomes will be the quality of life, the use of health and social resources, personal variables related to program adherence (patient activation in their own health, self-efficacy, sense of coherence, health literacy and procrastination) and chronic comorbid pathology. Data will be collected before and after the intervention, with 6- and 12-month follow-ups.
|
| Not Provided
|
| Interventional
|
| Not Applicable
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Investigator, Outcomes Assessor) Primary Purpose: Treatment
|
| Depression
|
|
|
- No Intervention: Control (TAU)
Patients will follow the usual treatment provided by their GP (treatment-as-usual, TAU).
- Experimental: Lifestyle Modification Program (LMP)
It will consist of 6 weekly group sessions (lasting 90 minutes each).
Interventions:
- Behavioral: Lifestyle Modification Program (LMP)
- Behavioral: Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)
- Experimental: Lifestyle Modification Program (LMP) + ICTs
It will consist of 6 weekly group sessions (lasting 90 minutes each).
Intervention: Behavioral: Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)
|
- Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97.
- Sanz J, Garcia Vera MP, Espinosa R, Fortun M, Vazquez C. Adaptación española del Inventario para la Depresión de Beck II: Propiedades psicométricas en pacientes con trastornos psicológicos. Clínica y Salud 2005; 16: 121-42.
- Badia X, Roset M, Montserrat S, Herdman M, Segura A. [The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]. Med Clin (Barc). 1999;112 Suppl 1:79-85. Review. Spanish.
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press; 2005.
- Kim Y, Park I, Kang M. Convergent validity of the international physical activity questionnaire (IPAQ): meta-analysis. Public Health Nutr. 2013 Mar;16(3):440-52. doi: 10.1017/S1368980012002996. Epub 2012 Jul 2.
- Martínez-González MÁ, Corella D, Salas-Salvadó J, Ros E, Covas MI, Fiol M, Wärnberg J, Arós F, Ruíz-Gutiérrez V, Lamuela-Raventós RM, Lapetra J, Muñoz MÁ, Martínez JA, Sáez G, Serra-Majem L, Pintó X, Mitjavila MT, Tur JA, Portillo MP, Estruch R; PREDIMED Study Investigators. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol. 2012 Apr;41(2):377-85. doi: 10.1093/ije/dyq250. Epub 2010 Dec 20.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.
- Sherer M, Maddux JE, Mercandante B, Prentice-Dunn S, Jacobs B, Rogers RW. The Self-Efficacy Scale: Construction and Validation. Psychol Rep 1982;51(2):663 -71.
- Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26.
- Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med. 1993 Mar;36(6):725-33.
- Sørensen K, Pelikan JM, Röthlin F, Ganahl K, Slonska Z, Doyle G, Fullam J, Kondilis B, Agrafiotis D, Uiters E, Falcon M, Mensing M, Tchamov K, van den Broucke S, Brand H; HLS-EU Consortium. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health. 2015 Dec;25(6):1053-8. doi: 10.1093/eurpub/ckv043. Epub 2015 Apr 5.
- Guilera G, Barrios M, Penelo E, Morin C, Steel P, Gómez-Benito J. Validation of the Spanish version of the Irrational Procrastination Scale (IPS). PLoS One. 2018 Jan 5;13(1):e0190806. doi: 10.1371/journal.pone.0190806. eCollection 2018.
- Ferrando, L., Bobes, J., Gibert, J., Soto, M. y Soto, O. (2000). MINI. Entrevista Neuropsiquiátrica Internacional. Versión en Español 5.0.0. DSM-IV. Traducida por L. Franco-Alfonso, L. Franco. Bajada de http://entomologia.rediris.es /pub/bscw.cgi/ d602335/ MINI/Entrevista Neuropsiquiátrica Internacional.pdf
- WHO. (2010). International Classification of Diseases (ICD-10). Family Practice Management.
- Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003 Aug 1;54(3):216-26. Review.
- Brooks R. EuroQol: the current state of play. Health Policy. 1996 Jul;37(1):53-72. Review.
- EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.
- Roman-Viñas, B., Serra-Majem, L., Hagströmer, M., Ribas-Barba, L., Sjöström, M., & Segura-Cardona, R. (2010). International physical activity questionnaire: Reliability and validity in a Spanish population. European Journal of Sport Science, 10(5), 297-304. https://doi.org/10.1080/17461390903426667
- Kurtze N, Rangul V, Hustvedt BE. Reliability and validity of the international physical activity questionnaire in the Nord-Trøndelag health study (HUNT) population of men. BMC Med Res Methodol. 2008 Oct 9;8:63. doi: 10.1186/1471-2288-8-63.
- Schröder H, Fitó M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Lamuela-Raventós R, Ros E, Salaverría I, Fiol M, Lapetra J, Vinyoles E, Gómez-Gracia E, Lahoz C, Serra-Majem L, Pintó X, Ruiz-Gutierrez V, Covas MI. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011 Jun;141(6):1140-5. doi: 10.3945/jn.110.135566. Epub 2011 Apr 20.
- Knapp, M. (2001). Economic Evaluation of Mental Health Care. In Contemporary Psychiatry. https://doi.org/10.1007/978-3-642-59519-6_16
- de la Revilla-Ahumada L, Luna del Castillo J, Bailón Muñoz E, M. M. I. (2005). [Validation of a questionnaire to measured social support in Primary Care]. Medicina de Familia (Andalucía).
- Royuela Rico, A., & Macías Fernández, J. A. (1997). Propiedades clinimétricas de la versión castellana del Cuestionario de Pittsburgh. Vigilia-Sueño.
- Moreno Chico, C., González de Paz, L., Monforte Royo, C., Navarro Rubio, M. D., & Gallart Fernández Puebla, A. (2018). Adaptación y validación de la escala de evaluación de la activación "Patient Activation Measure 13" (PAM13) en una muestra de pacientes crónicos visitados en CAP Rambla de MútuaTerrassa. XXIV Premi d'infermeria 2018.
- Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705-14.
- López-Torrecillas F, García J, Cañadas GA, Uclés IR, De La Fuente EI. Validity of self-efficacy scale scores for a Spanish sample. Psychol Rep. 2006 Apr;98(2):437-50.
- Moreno, B., Alonso, M., & Álvaréz, E. (1997). Sentido de coherencia, personalidad resistente, autoestima y salud. Revista de Psicología de La Salud, 9(2), 115-137.
- Nolasco, A., Barona, C., Tamayo-Fonseca, N., Irles, M. Á., Más, R., Tuells, J., & Pereyra-Zamora, P. (2018). Health literacy: psychometric behaviour of the HLS-EU-Q16 questionnaire. Gaceta Sanitaria, 8-11. https://doi.org/10.1016/j.gaceta.2018.08.006
- Steel, P. (2010). Arousal, avoidant and decisional procrastinators: Do they exist? Personality and Individual Differences. https://doi.org/10.1016/j.paid.2010.02.025
- Vazquez-Barquero, J. L., Gaite, L., Cuesta, M. J., Garcia, U. E., & Knapp, M. (1997). Spanish version of the CSRI: A mental health cost evaluation interview. [Spanish version of the CSRI: A mental health cost evaluation interview.]. Archivos de Neurobiología.
- Aguilar-Latorre A, Navarro C, Oliván-Blázquez B, Gervilla E, Magallón Botaya R, Calafat-Villalonga C, García-Toro M, Boira S, Serrano-Ripoll MJ. Effectiveness and cost-effectiveness of a lifestyle modification programme in the prevention and treatment of subclinical, mild and moderate depression in primary care: a randomised clinical trial protocol. BMJ Open. 2020 Dec 28;10(12):e038457. doi: 10.1136/bmjopen-2020-038457.
|
| |
| Completed
|
| 159
|
| 250
|
| February 1, 2021
|
| July 1, 2020 (Final data collection date for primary outcome measure)
|
|
Inclusion criteria:
- Individuals over the age of 18.
- Both sexes.
- Having a duration of depression symptoms of at least 2 months.
- Who perfectly understand written and spoken Spanish.
- Who have provided their informed consent.
Exclusion criteria:
- Suffering from another disease that affects the central nervous system (organic brain pathology or having suffered a traumatic brain injury of any severity, dementia).
- Having another psychiatric diagnosis or serious psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, eating disorders) with the exception of anxious pathology or personality disorders (collected through a medical history and from the Mini-International Neuropsychiatric Interview (MINI) (Ferrando, Bobes, & Gibert, 2000)).
- Presence of a serious or uncontrolled medical, infectious or degenerative illness that may interfere with the affective symptoms.
- Presence of delirium or hallucinations, risk of suicide, pregnancy or lactation.
- Patients who have participated in another clinical trial over the past 6 months or who are currently in psychotherapy.
- Who practice mindfulness, yoga, meditation or similar practices over the past 6 months, engaging in formal practice at least once a week.
- Presence of any medical, psychological or social problem that could seriously interfere with the patient's participation in the study.
|
| Sexes Eligible for Study: |
All |
|
| 18 Years and older (Adult, Older Adult)
|
| No
|
|
Contact information is only displayed when the study is recruiting subjects
|
| Spain
|
|
|
| |
| NCT03951350
|
| PI18/01336
|
| Not Provided
|
| Studies a U.S. FDA-regulated Drug Product: |
No |
| Studies a U.S. FDA-regulated Device Product: |
No |
|
| Plan to Share IPD: |
Yes |
| Plan Description: |
Proposals should be directed to barbaraolivan@gmail.com. To gain access, data requestors will need to sing a data access agreement. Data will be available for 5 years after we publish the results. |
| Supporting Materials: |
Study Protocol |
| Supporting Materials: |
Statistical Analysis Plan (SAP) |
| Supporting Materials: |
Informed Consent Form (ICF) |
|
| Bárbara Oliván-Blázquez, Instituto de Investigación Sanitaria Aragón
|
| Instituto de Investigación Sanitaria Aragón
|
| Not Provided
|
| Not Provided
|
| Instituto de Investigación Sanitaria Aragón
|
| February 2021
|